New Industries (300832.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 39...
According to the Zhitong Finance App, New Industry (300832.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 3.93 billion yuan, an increase of 28.97% over the previous year. Achieved net profit attributable to shareholders of listed companies of 1,654 billion yuan, an increase of 24.53% over the previous year. Achieved net profit of 1,547 billion yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 24.72% over the previous year. Basic earnings per share were $2.1054. It is proposed to distribute a cash dividend of 10 yuan (tax included) to all shareholders for every 10 shares.
In terms of domestic business, during the reporting period, the company continued its domestic market sales strategy in 2022. Through the continuous promotion of high-speed chemiluminescence analyzers MAGLUMIX8 and MAGLUMIX6, it effectively expanded the number of large-scale domestic medical terminal customers, which led to a steady increase in sales of conventional reagents; the number of tertiary hospitals served by the company increased 155 compared to the end of 2022, of which the number of customers in the top three hospitals increased by 67. In 2023, the domestic market completed the installation of 1,465 fully automatic chemiluminescence instruments, accounting for 63.34% of the installed capacity of large machines. As the number of medium and large terminal customers continues to increase, domestic reagent revenue and stand-alone output have increased rapidly. During the reporting period, domestic main business revenue was 2,601 billion yuan, up 25.53% year on year. As sales of large-scale light-emitting instruments and assembly line related products increased, domestic instrument product revenue increased by 33.53% year on year, higher than the overall domestic business growth rate; domestic reagent business revenue increased 23.73% year on year; as the number of large domestic medical terminal customers continued to increase, the installed capacity growth of domestic medium and large machines and assembly line products helped drive the continuous and steady growth of the company's domestic reagent business revenue.